Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1Lymphoid 1Head & Neck 1

Conditions

Lymphoma 15Lymphoma, Mantle-Cell 14Lymphoma, Large B-Cell, Diffuse 14Leukemia, Lymphocytic, Chronic, B-Cell 12Hodgkin Disease 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Waldenstrom Macroglobulinemia 10Lymphoma, Follicular 10Lymphoma, Non-Hodgkin 8Lymphoma, B-Cell, Marginal Zone 8Lymphoma, Large-Cell, Anaplastic 7Immunoblastic Lymphadenopathy 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, T-Cell, Cutaneous 6Burkitt Lymphoma 6Sezary Syndrome 5Recurrence 5Mycosis Fungoides 5Multiple Myeloma 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma, B-Cell 4Leukemia 4Neoplasms, Plasma Cell 3Lymphoproliferative Disorders 3Lymphoma, Large-Cell, Immunoblastic 3Primary Myelofibrosis 2Lymphoma, T-Cell 2Lymphatic Diseases 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2

Interventions

duvelisib 3parsaclisib 1obinutuzumab 1liposomal doxorubicin 1chiauranib 1Taxes 1Rituximab 1Panobinostat 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Everolimus 1Doxorubicin 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Everolimus × Lymphoid × Clear all
NCT01341834 2018-04-24

Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors

National Cancer Centre, Singapore

Phase 1 Unknown
49 enrolled
Head & NeckLymphoid

Nasopharyngeal Carcinoma, Lymphoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡